查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
支气管炎治疗药的全球市场 (2022～2030年):成长、未来展望、竞争分析
市场调查报告书
商品编码
1162481

支气管炎治疗药的全球市场 (2022～2030年):成长、未来展望、竞争分析

Bronchitis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

支气管炎治疗药的市场规模，2021年为35亿970万美元，预计从2022年～到2030年的预测期间中以4.9％的年复合成长率成长。

该市场，由于含标靶药物等强力的产品平台，支气管炎的盛行率和治疗、诊断的认知度上升，预计在整个预测期内显示阶段性的成长。持续性R&D预期支撑市场整体成长。

本报告提供全球支气管炎治疗药的市场调查，市场概要，市场成长的各种影响因素分析，市场规模的变化、预测，各种区分、各地区/主要国家的明细，主要企业简介等彙整资讯。

目录

第1章 序文

第2章 摘要整理

第3章 支气管炎治疗药市场:事业预测、市场动态

  • 世界市场规模:2020年～2030年
  • 市场动态
    • 推动市场要素
    • 阻碍市场要素
    • 主要课题
    • 主要的机会
  • 促进因素、阻碍因素的影响分析
  • See-Saw分析
  • 波特的五力分析
  • PESTEL分析

第4章 支气管炎治疗药市场:各类药物

  • 市场概要
  • 成长、收益分析
  • 市场分类
    • 止咳、祛痰药
    • 支气管扩张药
    • β肾上腺素促效剂
    • 全身性皮质类固醇
    • 吸入皮质类固醇
    • 磷酸二酯酶亚型四抑制剂
    • 止痛药
    • 抗生素

第5章 北美的支气管炎治疗药市场

  • 市场概要
  • 支气管炎治疗药市场:各类药物
  • 支气管炎治疗药市场:各地区

第6章 英国及EU的支气管炎治疗药市场

  • 市场概要
  • 支气管炎治疗药市场:各类药物
  • 支气管炎治疗药市场:各地区

第7章 亚太地区的支气管炎治疗药市场

  • 市场概要
  • 支气管炎治疗药市场:各类药物
  • 支气管炎治疗药市场:各地区

第8章 南美的支气管炎治疗药市场

  • 市场概要
  • 支气管炎治疗药市场:各类药物
  • 支气管炎治疗药市场:各地区

第9章 中东、非洲的支气管炎治疗药市场

  • 市场概要
  • 支气管炎治疗药市场:各类药物
  • 支气管炎治疗药市场:各地区

第10章 企业简介

  • Advanced Inhalation Therapies(AIT)Ltd.
  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd.
  • Han Wha Pharma Co. Ltd.
  • Kyorin Pharmaceutical Co Ltd.
  • Merck & Co.
  • Mucosis BV
  • Orbis Biosciences, Inc.
  • Therabron Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Chong Kun Dang Pharmaceutical
  • ONY Biotech Inc.
  • Genentech, Inc.
  • Daewon Pharm Co. Ltd.
Product Code: 138656-08-22

Industry Outlook

Bronchitis treatment market accounted for a market value of US$ 3,509.7 Mn in 2021 and is projected to grow at a CAGR of 4.9% during the forecast period from 2022 to 2030. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air-pollutants. Thus, overall growth of global bronchitis treatment is significant and expected to maintain its growth throughout the forecast year with the help of upcoming drugs currently present under trials.

Continuous research & development in the field of bronchitis treatment expected to bring novel drugs in the market & ultimately assist the overall growth

During the forecast period from 2022 to 2030, phospodiesterase-4inhibitors identified as the fastest growing segment due to major factors such as Roflumilast are beneficial in chronic bronchitis to decrease exacerbations & relieve dyspnea, and physicians treat chronic bronchitis on priority as its more complex compared to acute bronchitis. Roflumilast also plays key role in improving the lung function and assists recovery of patients. Thus, novel drugs entering in the market will increase the growth of overall bronchitis treatment market, as there is huge market demand for target-specific drugs in the market.

Increasing prevalence & awareness related to the bronchitis in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow significantly throughout the forecast period from 2022 to 2030, the key factors responsible for growth of bronchitis treatment market in this region are rising prevalence of bronchitis due to high level of air-pollution & smoking population, and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by government and non-government organizations in developing countries of Asia Pacific such as China, India, Indonesia, and Thailand due to which bronchitis treatment market is growing significantly in this region. China & India have highest population suffering with bronchitis that mainly caused due to air-pollution and huge cigarette smoking population. According to World Health Organization (WHO), it has been recorded that in Asia around one third or 2.2 million of the world's 7 million premature deaths occur due to respiratory disorders caused due to air-pollution each year.

The key manufacturers present in the market reported based on product portfolio, current market updates, financial information, and key strategies. This report also include attractive investment proposition studied with the aid of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bronchitis Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Bronchitis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antitussives/ Expectorants
  • Bronchodilators
  • Beta-adrenergic Agonist
  • Systemic Corticosteroids
  • Inhaled Corticosteroids
  • Phosphodiesterase-4 Inhibitors
  • Analgesics
  • Antibiotics

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Bronchitis Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Bronchitis Treatment market?
  • Which is the largest regional market for Bronchitis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Bronchitis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bronchitis Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Bronchitis Treatment Market
  • 2.2. Global Bronchitis Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Bronchitis Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Bronchitis Treatment Market Vendors
    • 2.6.2. Strategies Adopted by Bronchitis Treatment Market Vendors
    • 2.6.3. Key Industry Strategies

3. Bronchitis Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Bronchitis Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Antitussives/ Expectorants
    • 4.3.2. Bronchodilators
    • 4.3.3. Beta-adrenergic Agonist
    • 4.3.4. Systemic Corticosteroids
    • 4.3.5. Inhaled Corticosteroids
    • 4.3.6. Phosphodiesterase-4 Inhibitors
    • 4.3.7. Analgesics
    • 4.3.8. Antibiotics

5. North America Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 5.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Bronchitis Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Bronchitis Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Bronchitis Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Advanced Inhalation Therapies (AIT) Ltd.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. AstraZeneca Plc
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. DBV Technologies SA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Han Wha Pharma Co. Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Kyorin Pharmaceutical Co Ltd.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Merck & Co.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Mucosis BV
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Orbis Biosciences, Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Therabron Therapeutics, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives
  • 10.11. GlaxoSmithKline plc
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Portfolio
    • 10.11.4. Strategic Initiatives
  • 10.12. Chong Kun Dang Pharmaceutical
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Portfolio
    • 10.12.4. Strategic Initiatives
  • 10.13. ONY Biotech Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Portfolio
    • 10.13.4. Strategic Initiatives
  • 10.14. Genentech, Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Portfolio
    • 10.14.4. Strategic Initiatives
  • 10.15. Daewon Pharm Co. Ltd.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Portfolio
    • 10.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Latin America Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Bronchitis Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Bronchitis Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Bronchitis Treatment Market: Quality Assurance
  • FIG. 5 Global Bronchitis Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Bronchitis Treatment Market, By Geography, 2021
  • FIG. 7 Global Bronchitis Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 8 U.S. Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 France Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 China Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 India Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Bronchitis Treatment Market (US$ Million), 2020 - 2030